• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form NT 10-K filed by GridAI Technologies Corp.

    3/31/26 4:05:20 PM ET
    $GRDX
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $GRDX alert in real time by email
    NT 10-K 1 tm2610698d1_nt10k.htm NT 10-K

     

     

     

    UNITEDSTATES

    SECURITIES AND EXCHANGE COMMISSION

    Washington, D.C. 20549

     

    FORM 12b-25

     

    SEC FILE

    NUMBER

     
    CUSIP NUMBER

     

    NOTIFICATION OF LATE FILING

     

    (Check one):  x Form 10-K ¨ Form 20-F ¨ Form 11-K ¨ Form 10-Q ¨ Form 10-D ¨ Form N-CEN ¨ Form N-CSR

     

    For Period Ended December 31, 2025
       
    ¨ Transition Report on Form 10-K
    ¨ Transition Report on Form 20-F
    ¨ Transition Report on Form 11-K
    ¨ Transition Report on Form 10-Q
       
    For the Transition Period Ended ____________

     

    Nothing in this form shall be construed to imply that the Commission has verified any information contained herein.

     

    If the notification relates to a portion of the filing checked above, identify the Item(s) to which the notification relates:

     

    PART I - REGISTRANT INFORMATION
     
    GridAI Technologies Corp.
    Full Name of Registrant
     
    ENTERO THERAPEUTICS, INC.
    Former Name if Applicable
     
    777 Yamato Road, Suite 502
    Address of Principal Executive Office (Street and Number)
     
    Boca Raton, Florida, 33431
    City, State and Zip Code

     

     

     

     

     

     

    PART II - RULES 12b-25(b) AND (c)

     

    If the subject report could not be filed without unreasonable effort or expense and the registrant seeks relief pursuant to Rule 12b-25(b), the following should be completed. (Check box if appropriate).

     

    x (a) The reasons described in reasonable detail in Part III of this form could not be eliminated without unreasonable effort or expense;
    (b) The subject annual report, semi-annual report, transition report on Form 10-K, Form 20-F, 11-K Form N-CEN or Form N-CSR, or portion thereof, will be filed on or before the fifteenth calendar day following the prescribed due date; or the subject quarterly report of transition report on Form 10- Q or subject distribution report on Form 10-D, or portion thereof will be filed on or before the fifth calendar day following the prescribed due date; and
    (c) The accountant’s statement or other exhibit required by Rule 12b-25(c) has been attached if applicable.

     

    PART III - NARRATIVE

     

    State below in reasonable detail why Forms 10-K, 20-F, 11-K, 10-Q, 10-D, N-CEN, N-CSR, or the transition report or portion thereof, could not be filed within the prescribed time period.

     

    We are currently reviewing the accounting treatment and other information related to our recent acquisition of GridAI Corp. Due to the complexity of this matter, we require additional time to ensure that the financial statements are accurately presented in accordance with the relevant accounting standards. As such, we are requesting an extension for filing of our 10-K Annual Report for the year ended December 31, 2025. In accordance with Rule 12b-25 of the Securities Exchange Act of 1934, it is anticipated that the Registrant will file its Form 10-K no later than the fifteenth .calendar day following the prescribed due date.

     

    PART IV - OTHER INFORMATION

     

    (1) Name and telephone number of person to contact in regard to this notification

     

    Anna Skowron   416   312-0442
    (Name)   (Area Code)   (Telephone Number)

     

    (2) Have all other periodic reports required under Section 13 or 15(d) of the Securities Exchange Act of 1934 or Section 30 of the Investment Company Act of 1940 during the preceding 12 months or for such shorter period that the registrant was required to file such report(s) been filed? If answer is no, identify report(s). x Yes ¨ No
       
    (3) Is it anticipated that any significant change in results of operations from the corresponding period for the last fiscal year will be reflected by the earnings statements to be included in the subject report or portion thereof? ¨ Yes x No
       
      If so, attach an explanation of the anticipated change, both narratively and quantitatively, and, if appropriate, state the reasons why a reasonable estimate of the results cannot be made

     

     2 

     

     

    GridAI Technologies Corp.

    (Name of Registrant as Specified in Charter)

     

    has caused this notification to be signed on its behalf by the undersigned hereunto duly authorized.

     

    Date: March 31, 2026 By: /s/ Anna Skowron
        Anna Skowron
        Interim Chief Financial Officer

     

     3 

     

    Get the next $GRDX alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $GRDX

    DatePrice TargetRatingAnalyst
    More analyst ratings

    $GRDX
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Powell Max Limited Successfully Repositions for Its Next Phase of Growth

    Hong Kong, TX, March 09, 2026 (GLOBE NEWSWIRE) -- Powell Max Limited (NASDAQ:PMAX) ("Powell Max" or the "Company"), a financial communications services provider, is pleased to provide the following corporate update regarding its successful repositioning. Key Highlights: Raised $17 million in capital from new investorsAppointed new Chairman and Chief Executive Officer Geordan PursgloveReconstituted the Board of DirectorsRegained compliance with Nasdaq listing requirements Powell Max Chairman and Chief Executive Officer Geordan Pursglove commented, "My first month at Powell Max has been extremely productive. We successfully completed a corporate restructuring in a short timeframe, raised

    3/9/26 8:30:00 AM ET
    $ALBT
    $CISO
    $GRDX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Professional Services
    Consumer Discretionary

    IBN Announces Latest Episode of The TechMediaWire Podcast featuring Marshall Chapin, CEO of Grid AI Corp.

    AUSTIN, Texas, March 05, 2026 (GLOBE NEWSWIRE) -- via IBN – IBN, a multifaceted communications organization engaged in connecting public companies to the investment community, is pleased to announce the release of the latest episode of The TechMediaWire Podcast as part of its sustained effort to provide specialized content distribution via widespread syndication channels. The TechMediaWire Podcast delivers informative updates and exclusive interviews with executives operating in the tech industry. The TechMediaWire Podcast's latest episode features Marshall Chapin, CEO of Grid AI Corp., wholly-owned by GridAI Technologies Corp. (NASDAQ:GRDX), a technology company focused on intelligent en

    3/5/26 8:00:00 AM ET
    $GRDX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    GridAI Technologies Corp. Appoints Veteran Energy Executive Tim Healy as Executive Chairman of Grid AI Corp.

    BOCA RATON, Fla., Feb. 04, 2026 (GLOBE NEWSWIRE) -- via IBN – GridAI Technologies Corp. (NASDAQ:GRDX), a technology company focused on intelligent energy orchestration for hyperscale AI data centers, today announced the appointment of Tim Healy as Executive Chairman of the Board of Grid AI Corp., the Company's wholly owned operating subsidiary. Healy brings more than two decades of experience as a founder, CEO, board leader, and investor across the energy technology and energy transition landscape. Over his career, he has founded multiple public companies, establishing a track record of scaling innovative platforms from early commercialization through global deployment and strategic exits

    2/4/26 8:00:00 AM ET
    $GRDX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $GRDX
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Borkowski Edward was granted 40,000 shares, increasing direct ownership by 198% to 60,248 units (SEC Form 4)

    4 - GridAI Technologies Corp. (0001604191) (Issuer)

    1/8/26 5:28:29 PM ET
    $GRDX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Director Uppal Manpreet was granted 40,000 shares (SEC Form 4)

    4 - GridAI Technologies Corp. (0001604191) (Issuer)

    1/5/26 5:24:51 PM ET
    $GRDX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Director Pursglove Geordan Garrett was granted 40,000 shares (SEC Form 4)

    4 - GridAI Technologies Corp. (0001604191) (Issuer)

    1/5/26 4:57:27 PM ET
    $GRDX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $GRDX
    SEC Filings

    View All

    SEC Form NT 10-K filed by GridAI Technologies Corp.

    NT 10-K - GridAI Technologies Corp. (0001604191) (Filer)

    3/31/26 4:05:20 PM ET
    $GRDX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form RW filed by GridAI Technologies Corp.

    RW - GridAI Technologies Corp. (0001604191) (Filer)

    3/16/26 9:23:30 PM ET
    $GRDX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SCHEDULE 13G/A filed by GridAI Technologies Corp.

    SCHEDULE 13G/A - GridAI Technologies Corp. (0001604191) (Subject)

    2/12/26 2:14:12 PM ET
    $GRDX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $GRDX
    Leadership Updates

    Live Leadership Updates

    View All

    GridAI Technologies Corp. Appoints Veteran Energy Executive Tim Healy as Executive Chairman of Grid AI Corp.

    BOCA RATON, Fla., Feb. 04, 2026 (GLOBE NEWSWIRE) -- via IBN – GridAI Technologies Corp. (NASDAQ:GRDX), a technology company focused on intelligent energy orchestration for hyperscale AI data centers, today announced the appointment of Tim Healy as Executive Chairman of the Board of Grid AI Corp., the Company's wholly owned operating subsidiary. Healy brings more than two decades of experience as a founder, CEO, board leader, and investor across the energy technology and energy transition landscape. Over his career, he has founded multiple public companies, establishing a track record of scaling innovative platforms from early commercialization through global deployment and strategic exits

    2/4/26 8:00:00 AM ET
    $GRDX
    Biotechnology: Pharmaceutical Preparations
    Health Care